Related Experiment Video
Updated: Jun 26, 2026
05:47
Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro
Published on: May 10, 2021
Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention
Alessandro Parolari1, Claudia Loardi, Luciana Mussoni
1Department of Cardiac Surgery, Centro Cardiologico Monzino IRCCS, University of Milan, Milan, Italy. alessandro.parolari@cardiologicomonzino.it
Summary
Calcific aortic stenosis, a common heart valve disease, progresses through active biological processes similar to atherosclerosis. Current evidence suggests multi-factorial treatments targeting early disease stages are most effective for managing this condition.
Area of Science:
- Cardiovascular Medicine
- Pathology
- Pharmacology
Background:
- Calcific aortic stenosis is a prevalent degenerative heart valve disease, increasing with aging populations.
- Its progression involves active biological mechanisms resembling atherosclerosis, including inflammation and lipid deposition.
- Statins, used for atherosclerosis, have shown controversial benefits in preventing aortic stenosis progression.
Purpose of the Study:
- To review molecular mechanisms underlying calcific aortic stenosis.
- To discuss experimental and clinical studies on targeted drug therapies.
- To evaluate the effectiveness of interventions at different disease stages.
Main Methods:
- Literature review of basic science studies.
- Analysis of experimental research on molecular pathways.
- Evaluation of clinical trial data on drug efficacy.
Main Results:
- Aortic valve stenosis progression involves complex histological changes and active biological processes.
- Statin therapy has not consistently demonstrated significant benefits in moderate to severe cases.
- Early intervention targeting multiple pathways is crucial for effective pharmacological management.
Conclusions:
- Calcific aortic stenosis is a multi-factorial disease requiring multi-factorial therapeutic approaches.
- Pharmacological treatments are likely most effective when initiated in the early stages of the disease.
- Targeting the earliest stages of aortic valve stenosis is essential for potential therapeutic success.
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:15Aortic Regurgitation I: Introduction
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...